A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

Exclusion Criteria

• •Has received solid organ transplant at any time.
• •Has clinically significant (ie, active) cardiovascular disease: cerebral vascular accident/stroke (\<6 months prior to enrollment), myocardial infarction (\<6 months prior to enrollment), unstable angina (\<6 months prior to enrollment), congestive heart failure (New York Heart Association Classification Class ≥II), or serious cardiac arrhythmia requiring medication.
• •Has pericardial effusion or clinically significant pleural effusion.
• •Has ongoing Grade \>1 peripheral neuropathy.
• •Has a demyelinating form of Charcot-Marie-Tooth disease.
• •Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years.
• •Participants with FL who have transformed to a more aggressive type of lymphoma.
• •Has received prior systemic anticancer therapy within 5 half-lives or 4 weeks (if prior therapy was a monoclonal antibodies) or 2 weeks (if prior therapy was small molecules like kinase inhibitors) prior to the first dose of study intervention.
• •Has received prior radiotherapy within 28 days of start of study intervention. Participants must have recovered from all radiation-related toxicities.
• •Has ongoing corticosteroid therapy exceeding 30 mg daily of prednisone equivalent.
• •Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention.
• •Has known active central nervous system (CNS) lymphoma involvement or active CNS involvement by lymphoma.
• •Has an active infection requiring systemic therapy.
• •Has a known history of human immunodeficiency virus (HIV) infection not well controlled on antiretroviral therapy (ART)
• •Active HBV or hepatitis C virus (HCV) infection.
• •For Cohort C only: has any clinically significant gastrointestinal abnormalities that might alter absorption.